A deoxyribozyme targeting PD-L1 gene, a targeted delivery vector, a tumor-targeted nanocomplex and applications thereof
The tumor-targeting delivery vector APFP, prepared by modifying the PAMAM vector and nucleolin aptamer AS1411, electrostatically assembles deoxyribonuclease molecules, achieving precise delivery and efficient cleavage of the PD-L1 gene. This solves the problem of insufficient transport of deoxyribonuclease in vivo, significantly inhibits PD-L1 expression in melanoma cells, activates the immune response, and delays tumor progression.
Patent Information
- Application Number
- CN202210469898.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-04-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-04-28
AI Technical Summary
In existing technologies, deoxyribozymes have insufficient transport capacity in vivo, limited cellular uptake and bioavailability, resulting in low therapeutic efficiency and potential adverse reactions. Furthermore, the transfection efficiency and cytotoxicity of traditional PAMAM vectors limit their application.
Using polyamide-amine dendritic polymer PAMAM derivatives as carriers, and modifying nucleolin aptamer AS1411 with bifunctional polyethylene glycol molecules PEG, a tumor-targeting delivery carrier APFP was prepared. The carrier was electrostatically assembled into a nanocomposite to deliver deoxyribozyme molecules targeting the PD-L1 gene, achieving precise delivery and efficient cleavage.
This study achieved highly efficient targeted delivery of deoxyribonucleases to tumor cells, significantly inhibited PD-L1 expression, activated CD8+ T cells to kill tumor cells, delayed melanoma progression, and provided a new immunotherapy strategy for melanoma.
Smart Images

Figure CN115261384B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a tumor-targeted nanocomposite carrying a DNAzyme molecule and an application thereof in preparing a drug for treating melanoma. Background Art
[0002] Unlike traditional chemotherapy that directly acts on cancer cells, immunotherapy uses the patient's own immune system to eliminate tumors and has become a popular cancer treatment method today. The current mainstream cancer immunotherapies include T cell therapy, immune checkpoint blockade, cancer vaccine therapy, and immunomodulator therapy. These cancer immunotherapies effectively fight tumors by improving the T cell immunity of cancer patients. In particular, immune checkpoint blockade therapy targeting programmed cell death protein 1 (PD1) and its ligand programmed cell death ligand 1 (PD-L1) has provided clinical benefits for many cancers such as melanoma, non-small cell lung cancer, advanced renal cell carcinoma, and liver cancer. PD-L1 is a type I transmembrane protein encoded by the CD274 gene, belonging to the B7 family, also known as B7-H1. Studies have found that the expression of PD-L1 is significantly higher in various tumor cells such as lung cancer, ovarian cancer, colon cancer, and melanoma than in normal tissues. After PD-L1 binds to PD-1 on the surface of T cells, it promotes phosphorylation of tyrosine in the immune receptor tyrosine switch motif domain of PD-1, causing dephosphorylation of downstream spleen tyrosine kinase (Syk) and phosphoinositide-3-kinase (PI3K), thereby inhibiting the activation of downstream pathways such as protein kinase B (Akt) and extracellular signal-regulated kinase (ERK), and ultimately inhibiting the transcription and translation of genes and cytokines required for T cell activation, playing a role in negatively regulating T cell activity. Currently, a variety of targeted drugs targeting PD-L1 / PD-1 sites have been developed, and the marketed targeted antibodies targeting PD-L1, such as Atezolizumab, Avelumab, and Durvalumab, have shown good application prospects in clinical practice. By blocking the PD-1 / PD-L1 signaling pathway, T cells can be reactivated, providing a new strategy for anti-tumor immunotherapy.
[0003] Deoxyribozymes are single-stranded DNA molecules with high catalytic activity and stability. They can specifically cleave purine-pyrimidine-linked oligonucleotides in single-stranded RNA and catalyze RNA degradation. Deoxyribozymes have the advantages of low synthesis cost, high stability, programmability, and high activity. They can be used as a potential therapeutic molecule to inhibit the expression of tumor-related genes. Compared with immune checkpoint blockade therapy represented by antibodies, deoxyribozymes combine efficient catalytic degradation ability with targeted recognition ability, and can specifically block the expression of target genes from the mRNA level. In early studies, deoxyribozymes targeting the translation start site of vascular endothelial growth factor receptor 2 (VEGFR2) mRNA were shown to inhibit the growth of breast cancer in xenograft models. Deoxyribozymes targeting tumor angiogenesis-related genes, such as Dz13, have also been found to inhibit the proliferation of various tumors and have entered clinical trials. However, due to the inherent negative charge characteristics, deoxyribozymes have insufficient transport capacity in vivo, and cellular uptake and bioavailability are limited. In addition, systemic administration can also lead to off-target effects and produce unnecessary adverse reactions. To address these limitations, the development of delivery systems to enhance the therapeutic efficiency of DNA enzymes is crucial.
[0004] This patent uses polyamidoamine (PAMAM) derivatives as carriers to solve the problem of stable delivery of DNAzymes targeting PD-L1. PAMAM is a non-viral gene delivery vector with lower cytotoxicity and immunogenicity and simpler production than traditional viral vectors. The outermost amino group provides a high density of cationic charges, which can effectively bind and assemble nucleic acid molecules, protect them from degradation by nucleases, and accelerate the endosomal escape of nanocomplexes through the "proton sponge" effect. However, the overly tight compression makes the transfection efficiency of PAMAM unsatisfactory, and the high cytotoxicity also limits its application in gene delivery. Fortunately, the multiple amino groups on the surface of the PAMAM carrier provide favorable conditions for multifunctional modification. In previous studies, fluorinated modified PAMAM (FP) has been developed, which successfully reduced the toxicity of the vector and greatly improved the transfection efficiency, achieving efficient delivery of nucleic acid molecules (Nature Communications 2014, 5: 3053). Due to the widespread expression of PD-L1 on normal body cells, the specific delivery of DNAzymes to tumor cells is particularly important. Nucleolin is a multifunctional protein involved in ribosome biogenesis. In normal eukaryotic cells, it is mainly localized in the nucleus. However, in many tumor cells, the expression level of nucleolin is increased and ectopically located from the nucleus to the cell membrane surface. Nucleic acid aptamer AS1411 has been widely used as the "target head" of tumor-targeted delivery vectors because it can specifically target nucleolin. In this study, we used bifunctional polyethylene glycol molecules (PEG) as cross-linkers to modify AS1411 on the surface of the carrier FP to prepare a tumor-targeted delivery vector (AS1411-PEG-FP, named APFP); it was electrostatically assembled with deoxyribozymes to form a nanocomplex, thereby achieving the precise delivery of deoxyribozymes to the tumor site and the immune effect, ultimately providing a new strategy for melanoma immunotherapy. Summary of the invention
[0005] The purpose of the present invention is to provide a tumor-targeted nanocomposite carrying a DNAzyme molecule and its application in preparing a drug for treating melanoma.
[0006] According to the mRNA sequence (NC_000085.7) encoding mouse PD-L1 (CD274), the present invention designs and constructs a DNAzyme molecule targeting the PD-L1 gene that effectively reduces the expression of PD-L1 in tumor cells to activate T cell immunity, thereby accurately treating tumors. At the same time, in order to solve the problem of stable delivery of the DNAzyme molecule targeting the PD-L1 gene, the present invention uses polyamidoamine (PAMAM, FP) derivatives as carriers and bifunctional polyethylene glycol molecules (PEG) as cross-linking agents to modify the nucleolin aptamer AS1411 on the surface of the carrier FP, and prepares a tumor-targeted delivery carrier (AS1411-PEG-FP, named APFP). APFP is used as a transfection reagent to accurately deliver the DNAzyme molecule targeting the PD-L1 gene into tumor cells; through the specific recognition and efficient cleavage of the target gene PD-L1 mRNA sequence by the DNAzyme molecule targeting the PD-L1 gene, the expression of PD-L1 is downregulated, thereby restoring CD8 + Specific killing of melanoma cells by T cells.
[0007] The deoxyribozyme molecules (Dz1~Dz10) targeting the PD-L1 gene described in the present invention are 10-23 type deoxyribozymes, which have the chemical stability of antisense oligonucleotides and the function of catalytic RNA cleavage of ribozymes. The specific sequence includes: a central catalytic function sequence and two target gene binding arms on both sides, wherein the catalytic function sequence is composed of 15 deoxyribonucleotides, and its specific sequence is 5'-GGCTAGCTACAACGA-3'; the first target gene binding arm connected to the 5' end of the catalytic function sequence is composed of 9 deoxyribonucleotides, which is complementary to the 3' end sequence of the R↓Y cleavage site of the PD-L1 gene mRNA; the second target gene binding arm connected to the 3' end of the catalytic function sequence is composed of 9 deoxyribonucleotides, which is complementary to the 5' end sequence of the R↓Y cleavage site of the PD-L1 gene mRNA (where ↓ represents the cleavage point, R represents A or G, Y represents U or C, R does not form base pairing, and Y must form base pairing with the deoxyribozyme). In addition, the conserved catalytic domains in Dz4 and Dz6 were replaced with nonsense sequences, and catalytically inactive deoxyribozymes iDz4 and iDz6 were designed as negative controls. The specific sequences are shown in the sequence table. The sequences of the deoxyribozyme molecules Dz1~Dz10 targeting the PD-L1 gene and the deoxyribozymes iDz4 and iDz6 without catalytic activity described in the present invention are shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11 or SEQID NO.12:
[0008] 1. Dz1:5'-GTGCAAGTGGGCTAGCTACAACGAAGCCTGGCA-3'
[0009] 2. Dz2:5'-ATATCCTCAGGCTAGCTACACGAGTTTTGGGA-3'
[0010] 3. Dz3:5'-TGAATATAAGGCTAGCTACAACGAGCCAGCAAA-3'
[0011] 4. Dz4:5'-CTGTGAATAGGCTAGCTACAACGAAATGCCAGC-3'
[0012] 5. Dz5:5'-CACCACGTAGGCTAGCTACAACGAAAGTCCTTT-3'
[0013] 6. Dz6:5'-AGTACACCAGGCTAGCTACAACGATAACGCAAG-3'
[0014] 7. Dz7:5'-CCTCTCCTGGGCTAGCTACAACGACACAAACTG-3'
[0015] 8. Dz8: 5'-AGGGCAGCAGGCTAGCTACAACGATTCCCTTCA-3'
[0016] 9. Dz9: 5'-GAAGGGCAGGGCTAGCTACAACGAATTTCCCTT-3'
[0017] 10. Dz10: 5'-TCAGCGTGAGGCTAGCTACAACGAACGCTTGTA-3'
[0018] 11. iDz4: 5'-CTGTGAATGGCTACCTACAACGAAAATGCCAGC-3'
[0019] 12. iDz6: 5'-AGTACACCGGCTACCTACAACGAATAACGCAAG-3'
[0020] The enhancement of the stability of the DNA enzyme in the present invention can be achieved by chemically modifying the binding sequence, and the phosphate group constituting the DNA enzyme is modified at the free single-bond oxygen position of the natural phosphodiester bond part to improve the ability of the DNA enzyme to resist acid and enzyme degradation. The DNA enzyme of the present invention is modified by phosphorothioate diester bonds, so that the two target gene binding sequences each contain 2 to 3 phosphorothioate diester bonds.
[0021] The present invention also relates to a tumor-targeted delivery vector, which is prepared by the following steps:
[0022] (1) Dissolve 45-55 mg PAMAM (FP, Weihai Chenyuan Molecular New Materials Co., Ltd., China) and 50-60 mg heptafluorobutyric anhydride (Sigma-Aldrich, USA) in 6-10 mL methanol, stir at room temperature for 36-50 h, then place in a dialysis bag with a molecular weight cutoff of 3000-4000 Da and dialyze in deionized water for 48-72 h. The dialyzed product in the bag is freeze-dried overnight to obtain a fluorinated PAMAM carrier powder;
[0023] (2) Take 50-60 mg of the fluorinated modified PAMAM carrier powder obtained in step (1) and dissolve it in 2-4 mL of PBS solution to obtain solution A; take another 70-80 mg of maleimide-polyethylene glycol-succinimide ester (Mal-PEG 5000 -NHS) or methoxy-polyethylene glycol-succinimidyl ester (mPEG 5000 -NHS) (both purchased from Beijing Jiankai Technology Co., Ltd., China) were dissolved in 2-4 mL of PBS solution to obtain solution B; solution A and solution B were mixed and stirred at room temperature for 36-50 h, then placed in a dialysis bag with a molecular weight cutoff of 7000-9000 Da and dialyzed in deionized water for 48-72 h. The dialyzed product in the bag was freeze-dried overnight to obtain Mal-PEG 5000 -FP or mPEG 5000 -FP (named PFP, as a non-targeted control carrier) powder;
[0024] (3) OD 260 The thiol-modified aptamer AS1411 (5′-GGTGGTGGTGGTTGTGGTGGTGGTGGTTTTTTTTTT-C6-SH-3′, synthesized by Sangon Biotechnology Co., Ltd.) with a molar mass of 15-30 was dissolved in 4-6 mL of PBS solution, and tris(2-carboxyethyl)phosphine (TCEP) with a final concentration of 8-12 mM was added, followed by stirring at room temperature for 1-2 h to obtain solution C. 40-50 mg of Mal-PEG obtained in step (2) was taken. 5000 -FP powder was dissolved in 4-6 mL PBS solution to obtain solution D; solution C and solution D were mixed, stirred at room temperature for 20-30 h, and then placed in a dialysis bag with a molecular weight cutoff of 7000-9000 Da, dialyzed in deionized water for 48-72 h, and the dialyzed product in the bag was freeze-dried overnight to obtain the dendritic polymer derivative, which is the tumor-targeted delivery carrier AS1411-PEG-FP (named APFP) powder of the present invention.
[0025] The carrier APFP used for achieving targeted delivery of DNAzymes in the present invention is a highly efficient tumor-targeted delivery carrier with low cytotoxicity. APFP can selectively deliver DNAzymes to tumor sites by virtue of the recognition and binding ability of nucleic acid aptamer AS1411 to highly expressed nucleolin on the surface of tumor cells, and escape from lysosomes through the "proton sponge" effect, thereby achieving the release of DNAzymes and the subsequent cleavage effect.
[0026] The present invention also relates to a tumor-targeted nanocomposite carrying a deoxyribozyme molecule, which is prepared by the following steps: dissolving a deoxyribozyme molecule (Dz1~Dz10) powder targeting the PD-L1 gene and an APFP powder in a mass ratio of 1:20~100 in nuclease-free water (Thermo Fisher Scientific, USA) and mixing them evenly, and then incubating at 0~40°C for 20~40 min to obtain a tumor-targeted nanocomposite APFP / Dz1~10 carrying a deoxyribozyme molecule.
[0027] The tumor-targeted nanocomplex loaded with DNAzyme molecules constructed by the present invention has precise tumor cell targeting, and the DNAzyme molecules (Dz1~Dz10) targeting the PD-L1 gene efficiently cut the activity and chemical stability of the PD-L1 gene. The drug was administered to mice with melanoma lung metastasis as a tumor model, and the system was able to inhibit the expression of PD-L1 in melanoma cells, thereby activating CD8 + T cells kill tumor cells and inhibit the development of melanoma in mice.
[0028] In summary, the present invention simulates the secondary structure of PD-L1 gene mRNA, designs and screens DNAzyme molecules (Dz1~Dz10) targeting PD-L1 gene with high target gene recognition and cleavage activity; then a series of modifications are made to the dendritic polymer PAMAM to obtain APFP, a tumor-targeted delivery vector with low cytotoxicity and high transfection efficiency; DNAzyme molecules (Dz1~Dz10) and tumor-targeted delivery vector APFP are electrostatically assembled to prepare tumor-targeted nanocomplexes, which effectively inhibits the expression of PD-L1 gene in melanoma cells. With the help of APFP vector, Dz1~Dz10 achieves precise delivery to the tumor site in mice with melanoma lung metastasis, significantly inhibits the expression of PD-L1 in tumor cells, and successfully activates CD8 + The tumor-killing activity of T cells is enhanced, thereby delaying the progression of metastatic melanoma in mice, providing a new strategy for melanoma immunotherapy. Furthermore, the deoxyribozyme molecules (Dz1~Dz10) targeting the PD-L1 gene, the tumor-targeted delivery vector APFP, and the tumor-targeted nanocomplex APFP / Dz1~10 carrying the deoxyribozyme molecules described in the present invention can be used to prepare drugs for the treatment of melanoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 : Secondary structure simulation diagram of target gene PD-L1 mRNA.
[0030] Figure 2 : Relative quantitative graph of PD-L1 mRNA expression in mouse melanoma cells B16F10 after DNAzyme treatment.
[0031] Figure 3 : PD-L1 protein expression in mouse melanoma cells B16F10 after DNAzyme treatment.
[0032] Figure 4 :400 MHz of tumor-targeted vector APFP 1 H NMR spectrum.
[0033] Figure 5 : Schematic diagram of the cytotoxicity of FP and APFP vectors to mouse melanoma cells B16F10.
[0034] Figure 6 : Particle size and potential analysis diagrams of FP / Dz, PFP / Dz and APFP / Dz nanocomposites at different N / P ratios.
[0035] Figure 7 : Transmission electron microscopy images of PFP / Dz and APFP / Dz nanocomposites when the N / P ratio is 20.0.
[0036] Figure 8 : Fluorescence microscopy image of targeting detection of APFP / Dz4 nanocomplex on mouse melanoma cells B16F10.
[0037] Fig. 9 : Relative quantitative graph of PD-L1 mRNA expression in mouse melanoma cells B16F10 after treatment with APFP / Dz4 nanocomplex. * indicates P <0.05, ** indicates P <0.01, *** indicates P <0.001.
[0038] Fig.10 : PD-L1 protein expression in mouse melanoma cells B16F10 after treatment with APFP / Dz4 nanocomplex.
[0039] Fig.11 :APFP / Dz4 nanocomplexes treat mouse melanoma cells B16F10 and CD8 + CFSE method for detecting CD8 in T cell co-culture system + Flow cytometry of T cell proliferation.
[0040] Fig.12 :MTT assay to detect the effects of APFP / Dz4 nanocomplex on mouse melanoma cells B16F10 and CD8 + Relative quantitative graph of B16F10 cell viability in T cell co-culture system. ns indicates no significant difference, * indicates P <0.05, ** indicates P<0.01, *** indicates P <0.001.
[0041] Fig.13 : ELISA method was used to detect the expression of APFP / Dz4 nanocomplex in mouse melanoma cells B16F10 and CD8 + Quantitative plots of immune-related cytokines IFN-γ (A), IL-2 (B), and TNF-α (C) in the supernatant of T cell co-culture system. ns indicates no significant difference, * indicates P <0.05, ** indicates P <0.01, *** indicates P <0.001.
[0042] Fig.14 : Distribution of APFP / Cy5-Dz4 nanocomplexes in various organs of mice with melanoma lung metastasis.
[0043] Fig.15 :Flowchart of establishment and drug administration of melanoma lung metastasis mouse model.
[0044] Fig.16 :Lung images of mice with melanoma lung metastasis 21 days after different treatments
[0045] Fig.17 :Flow cytometry was used to detect the level of infiltrating T lymphocytes in mouse tumor tissues.
[0046] Fig.18 :CD8 in total T cells infiltrating mouse tumor tissue + T cells and CD4 + T cell ratio analysis.
[0047] Fig.19 :Total T cells infiltrating mouse tumor tissue (A) and their CD8 + T cells / CD4 + T cell ratio (B) Quantitative graph. ns indicates no significant difference, * indicates P <0.05, ** indicates P <0.01, *** indicates P <0.001.
[0048] Fig. 20 : Immunohistochemical staining of immune-related indicators in lung tumor tissue of mice with melanoma lung metastasis after treatment with different drugs.
[0049] Fig.21 : ELISA quantitative graph of immune-related cytokines in lung tumor tissue of mice with melanoma lung metastasis after treatment with different drugs. ns indicates no significant difference, * indicates P <0.05, ** indicatesP <0.01, *** indicates P <0.001. DETAILED DESCRIPTION
[0050] The following examples are provided to further illustrate the present invention, so that those skilled in the art can more fully understand the present invention. However, the examples provided cannot be understood as limiting the scope of protection of the present invention, and thus non-essential improvements and adjustments made by those skilled in the art based on the above-mentioned invention content should also fall within the scope of protection of the present invention.
[0051] Example 1
[0052] According to the mRNA sequence of mouse PD-L1 gene (NC_000085.7), RNAdraw V1.1b2 software was used to simulate the mRNA secondary structure under physiological conditions. The results are as follows Figure 1 As shown in the figure, PD-L1 mRNA folds under physiological conditions to form a stable secondary structure, which includes multiple relatively loose loop regions. According to the design principles of DNAzymes, the vulnerable loop region in the secondary structure was selected as the target site region, and ten DNAzyme oligonucleotide sequences Dz1~Dz10 were designed. In addition, the conserved catalytic domains in Dz4 and Dz6 were replaced with nonsense sequences, and catalytically inactive DNAzymes iDz4 and iDz6 were designed. The specific sequences are as follows:
[0053] 1. Dz1:5'-GTGCAAGTGGGCTAGCTACAACGAAGCCTGGCA-3'
[0054] 2. Dz2:5'-ATATCCTCAGGCTAGCTACACGAGTTTTGGGA-3'
[0055] 3. Dz3:5'-TGAATATAAGGCTAGCTACAACGAGCCAGCAAA-3'
[0056] 4. Dz4:5'-CTGTGAATAGGCTAGCTACAACGAAATGCCAGC-3'
[0057] 5. Dz5:5'-CACCACGTAGGCTAGCTACAACGAAAGTCCTTT-3'
[0058] 6. Dz6:5'-AGTACACCAGGCTAGCTACAACGATAACGCAAG-3'
[0059] 7. Dz7:5'-CCTCTCCTGGGCTAGCTACAACGACACAAACTG-3'
[0060] 8. Dz8: 5'-AGGGCAGCAGGCTAGCTACAACGATTCCCTTCA-3'
[0061] 9. Dz9: 5'-GAAGGGCAGGGCTAGCTACAACGAATTTCCCTT-3'
[0062] 10. Dz10: 5'-TCAGCGTGAGGCTAGCTACAACGAACGCTTGTA-3'
[0063] 11. iDz4: 5'-CTGTGAATGGCTACCTACAACGAAAATGCCAGC-3'
[0064] 12. iDz6: 5'-AGTACACCGGCTACCTACAACGAATAACGCAAG-3'
[0065] Each DNAzyme molecule has two nucleotides at both ends that are thiolated and sent to Sangon Biotech Co., Ltd. for synthesis. DNAzyme powder is obtained by HPLC grade purification.
[0066] Example 2
[0067] Real-time fluorescence quantitative PCR was used to detect the expression of PD-L1 mRNA in mouse melanoma cells B16F10 after DNAzyme treatment. 5 Mouse melanoma B16F10 cells (preserved in our laboratory) were seeded into 6-well plates at a density of 10 cells / well. 2 mL of DMEM cell culture medium (ThermoFisher Scientific, USA) containing 10% (v / v) fetal bovine serum (Kangyuan Biopharmaceutical Co., Ltd., China) and 1% (v / v) penicillin and streptomycin (Sigma-Aldrich, USA) (complete culture medium) was added to each well and incubated at 37°C with 5% (v / v) CO 2The cells were cultured overnight in an incubator. PD-L1-targeting siRNA was used as a positive control (sense strand: 5'-AGACGUAAGCAGUGUUGAAdTsdT-3'; antisense strand: 5'-UUCAACACUGCUUACGUCUdTsdT-3', synthesized by Shanghai Jima Pharmaceutical Technology Co., Ltd.). The commercial transfection reagent polyethyleneimine (PEI25K) (Sigma-Aldrich, USA) was mixed with DNAzymes (Dz1~Dz10) or siRNA at a mass ratio of 1.33:1, incubated at 37°C for 30 min, and added to the cell culture system to make the final concentration of DNAzymes in the culture medium 3 μg / mL and the concentration of siRNA 100 nM. A negative control group, i.e., the Control group, was set up with cells only but no drugs added. The cells were cultured in serum-free DMEM medium for 6 h, and then cultured in DMEM complete medium for 48 h. Cells were collected, and TRNzol Universal total RNA extraction reagent (Tiangen Biochemical Technology Co., Ltd., China) was used to lyse the cells in each group, and total RNA was extracted according to the instructions of the kit. 1 μg of total RNA was taken and reverse transcribed using the reverse transcription PrimeScript RT reagent kit (TAKARA, Japan) to obtain cDNA. The dye-based fluorescence quantitative SYBRs Premix Ex Taq kit (TAKARA, Japan) was used to detect the expression of PD-L1 mRNA in the cDNA of each group. After adding cDNA, SYBR® PremixEx TaqTM, ROXReference Dye II and corresponding primers in the kit, water was added to make up to 20 μL system, and the cycle number (Ct) value of each group of samples was detected by real-time fluorescence quantitative polymerase chain reaction (qRT-RCR) instrument. The 2-ΔΔCt method was used to calculate the expression of PD-L1 mRNA based on the Ct value of β-actin. The corresponding mRNA amplification primer sequences are as follows (synthesized by Sangon Biotech Co., Ltd.):
[0068] β-actin: forward primer: 5′- AGTGTGACGTTGACATCCGT -3′;
[0069] Reverse primer: 5'-GCAGCTCAGTAACAGTCCGC -3'.
[0070] PD-L1: forward primer: 5′-GGGTTCTCTTCTTCCTGACGACC-3′;
[0071] Reverse primer: 5′-CACCTTCACCGTTCCAGTTT-3′.
[0072] The results are as follows Figure 2 As shown in the figure, compared with the Control group, the PEI25K transfection reagent alone had no effect on the PD-L1 expression level, while the transfection of the ten DNAzymes reduced the expression of PD-L1 in B16F10 cells to varying degrees. Among them, the transfection effect of the Dz4 group was the most significant, and its PD-L1 expression level was slightly lower than that of the siRNA transfection group, indicating that Dz4 has a higher PD-L1 cleavage activity and can effectively reduce the expression of PD-L1 in tumor cells, and its effect is slightly better than that of PD-L1 targeted siRNA.
[0073] Example 3
[0074] Western blotting was used to detect the expression of PD-L1 protein in mouse melanoma cells B16F10 after DNAzyme treatment. siRNA, Dz4 and nonsense DNAzyme iDz4 targeting PD-L1 were transfected into mouse melanoma cells B16F10 as described in Example 2, and culture was continued for 48 h. The treated cells were collected and lysed on ice using radio-immunoprecipitation assay (RIPA) lysis buffer with protease inhibitor phenylmethylsulfonyl fluoride (PMSF) added. The cells were flicked every 15 min to mix, and the lysis was continued for 1 h. The total cell protein was extracted and protein was quantified using the bicinchinicacid (BCA) method. 5× sodium dodecyl sulfate (SDS) loading buffer was added to the sample, and 100 oDenatured at 40 °C for 15 min. The obtained protein samples were separated by 12% (m / m) SDS polyacrylamide gel electrophoresis and transferred to poly(1,1-difluoroethylene) PVDF membrane at 300 mA constant current on ice for 3 h. Skim milk powder was dissolved in phosphate buffered saline (PBS solution) containing 0.1% (v / v) Tween-20 to a final mass concentration of 5%. The PVDF membrane with protein was blocked with this solution at room temperature for 2 h to remove nonspecific binding of protein. Antibodies were diluted to an appropriate ratio (PD-L11: 1000; β-actin 1: 5000, purchased from Abcam, USA) in PBS solution containing 3% bovine serum albumin (BSA) by mass, and incubated with shaking at 4 °C overnight. After washing three times with PBS solution containing 0.1% (v / v) Tween-20, add the corresponding species of horseradish peroxidase (HRP) labeled secondary antibody and incubate at room temperature for 1 h. After washing three times with PBS solution containing 0.1% Tween-20 (v / v), the membrane was developed with an enhanced chemiluminescence kit and photographed.
[0075] like Figure 3 As shown, the DNAzyme molecule Dz4 prepared by the present invention reduces the expression of PD-L1 at the protein level, and its effect is better than that of the siRNA treatment group targeting PD-L1. However, the cells transfected with nonsense DNAzyme iDz4 did not show a decrease in the expression level of PD-L1 protein, indicating that the effect of DNAzyme depends on the combination of specific targeting binding sequence and target gene, and the DNAzyme Dz4 designed by the present invention can specifically and efficiently inhibit the expression of PD-L1 protein in melanoma cells B16F10.
[0076] Example 4
[0077] Preparation process of APFP, a DNAzyme targeted delivery carrier: 50 mg PAMAM (Weihai Chenyuan Molecular New Materials Co., Ltd., China) and 54.12 mg heptafluorobutyric anhydride (Sigma-Aldrich, USA) were dissolved in 8 mL methanol solution, stirred at room temperature for 48 h, and the mixture was placed in a dialysis bag with a molecular weight cutoff of 3500 Da, dialyzed in deionized water for 72 h, and freeze-dried overnight into powder. The resulting product was the fluorinated modified carrier FP. Take 50 mg FP powder and dissolve it in 2 mL PBS solution, and take 75 mg Mal-PEG 5000-FP was dissolved in 2 mL PBS solution, the two solutions were mixed, stirred at room temperature for 48 h, the mixture was placed in a dialysis bag with a molecular weight cutoff of 8000 Da, dialyzed in deionized water for 72 h, and freeze-dried overnight into powder. The obtained product was the PEG-modified carrier Mal-PEG-FP. 260 The thiolated aptamer AS1411 with a concentration of 20 was dissolved in 4 mL of PBS solution, and TCEP with a final concentration of 10 mM was added and stirred at room temperature for 1 h. Another 48 mg of PEG-modified carrier Mal-PEG-FP was dissolved in 4 mL of PBS solution. The two solutions were mixed and stirred at room temperature for 24 h, then placed in a dialysis bag with a molecular weight cutoff of 8000 Da, dialyzed in deionized water for 72 h, and freeze-dried overnight to form a powder, which is the tumor-targeted delivery carrier AS1411-PEG-FP described in the present invention, named APFP. In addition, in the above method, the single-ended mPEG was added 5000 -NHS without adding bifunctional Mal-PEG 5000 -NHS, and was not cross-linked with AS1411 to prepare a non-targeted PEG-modified carrier, named PFP.
[0078] The structure of the carrier APFP prepared by the above method was characterized as follows: the freeze-dried APFP was dissolved in D 2 O, at 400 MHz using 1 H NMR analysis of the product structure. The results are as follows Figure 4 As shown, at δ = 2.28 (-NCH 2 C H 2 CO-); 2.49 (-CONHCH 2 C H 2 NH 2 );2.68(-CONHCHC H 2 N-); 2.92 (-NC H 2 CH 2 CO-);3.16 (-CONHC H 2 CH 2 N-) and 3.32 (-CONHC H 2 CH 2 NH 2 -), and at the same time, there is an obvious PEG characteristic peak at δ=3.58 ppm, which proves the successful modification of PEG on the surface of FP molecule.
[0079] Example 5
[0080] The toxicity test process of APFP and FP vectors is as follows: 7×10 3 Mouse melanoma B16F10 cells were seeded into 96-well plates at a density of 10 cells / well. 200 μL of DMEM complete medium was added to each well and the plates were incubated at 37°C with 5% (v / v) CO 2 Cultured overnight in an incubator. When the cell confluence reached 70%, the culture medium was replaced with DMEM culture medium containing only different concentrations of APFP or FP carrier (0-160 μg / mL). A negative control group (only DMEM culture medium) and a blank control group were set up, with 6 replicates in each group. After 48 h of continuous culture, 20 μL of MTT solution (5 mg / mL) was added to each well, incubated at 37 °C for 4 h, and the culture medium was discarded. 200 μL of dimethyl sulfoxide (DMSO) was added to each well and shaken for 3 min to fully dissolve the formazan crystals, and the absorbance (OD) value of each well at 490 nm was recorded. The cell viability calculation formula is as follows:
[0081] Cell survival rate (%) = (A sample -A blank ) / (A control -A blank )×100%
[0082] Among them, A sample are the OD values measured after adding different concentrations of APFP or FP carrier, A control A is the OD value measured after normal cell culture in DMEM medium. blank The OD value is measured after adding only DMEM cell culture medium without cells.
[0083] like Figure 5 As shown in the figure, with the increase of FP vector concentration, the proliferation inhibition effect on mouse melanoma cell B16F10 also increased significantly, while the modified APFP vector showed no significant cytotoxicity at all concentrations, and the cell survival rate was still higher than 75% at a concentration of 160 μg / mL. The above results show that the APFP vector prepared by the present invention has low cytotoxicity.
[0084] Example 6
[0085] Particle size and potential analysis of FP / Dz4, PFP / Dz4 and APFP / Dz4 nanocomposites: 10 μL of 1 μg / μL DNAzyme aqueous solution was mixed with different concentrations of FP, PFP or APFP aqueous solution and incubated at 37 °C for 30 min to obtain FP / Dz4, PFP / Dz4 and APFP / Dz4 nanocomposites with different N / P ratios. 20 μg of FP / Dz4, PFP / Dz4 and APFP / Dz4 nanocomposites with different N / P ratios were dissolved in ultrapure water, so that the final concentration of each sample in water was 20 μg / mL. The particle size and potential of the three nanocomposites were analyzed using Zetasizer Nano ZS90 particle size potential analyzer (Malvern, UK).
[0086] like Figure 6 As shown, the positive charge of FP / Dz4, PFP / Dz4 and APFP / Dz4 nanocomplexes decreases in turn. This decrease in charge is caused by the modification of PEG and aptamer AS1411, and can also reduce the toxicity of the carrier to cells. Due to the positive charge of the carrier itself, the positive charge of each nanocomplex shows an upward trend as the carrier ratio increases. Due to the higher positive charge, the volume of the FP / Dz4 nanocomplex is further compressed as the FP ratio increases, showing a trend of gradually shrinking; while for PFP / Dz4 and APFP / Dz4 nanocomplexes, the volume increases due to the modification of PEG and AS1411 weakening the positive charge of the carrier, and the volume increases, and it is more significant as the carrier ratio increases. When the N / P ratio is 20.0, the particle size of the APFP / Dz4 nanocomplex is about 200nm, and the potential is about +10 mV, so this ratio is the optimal ratio for transfection of the DNAzyme Dz4 and the tumor targeting delivery carrier APFP in the present invention.
[0087] Example 7
[0088] Transmission electron microscopy examination of the morphology of PFP / Dz4 and APFP / Dz4 nanocomposites: 10 μL of the PFP / Dz4 and APFP / Dz4 nanocomposites with an N / P ratio of 20.0 prepared in Example 6 were dropped onto a 300-mesh carbon film-coated copper grid, respectively, and dried at room temperature. The copper grid coated with the nanocomposites was examined and photographed using a JEM-2100 transmission electron microscope (JEOL Ltd.) at an accelerating voltage of 200 kV.
[0089] like Figure 7 As shown, both PFP / Dz4 and APFP / Dz4 nanocomposites have a uniform spherical structure with a particle size of about 200 nm, indicating that both PFP and APFP carriers can effectively bind and compress Dz4 to form stable nanoparticles.
[0090] Example 8
[0091] Fluorescence microscopy confirmed the tumor cell targeting of APFP vector: 2×10 5 Mouse melanoma cells B16F10 or mouse fibroblasts NIH-3T3 (long-term stored in our laboratory) were seeded into 6-well plates at a density of 10 cells / well. 2 mL of complete medium was added to each well and the plates were incubated at 37°C with 5% (v / v) CO 2 The cells were cultured overnight in an incubator. When the cell confluence reached 70%, free aptamer AS1411 (5′-GGTGGTGGTGGTTGTGGTGGTGGTGGTTTTTTTTTT-3′, synthesized by Sangon Biotech Co., Ltd.) (0.25 OD260 / well) was added and cultured for 1 h to cover the nucleolin on the cell membrane surface. Carboxyfluorescein succinimidyl ester (FAM)-labeled Dz4 was synthesized by Sangon Biotech Co., Ltd. and was denoted as FAM-Dz4. FAM-Dz4 was used to prepare fluorescently labeled PFP / FAM-Dz4 or APFP / FAM-Dz4 nanocomplexes (N / P ratio of 20.0) as described in Example 6, added to serum-free DMEM culture medium and replaced the original cell culture medium, so that the concentration of DNAzyme in the culture medium was 3 µg / mL. After incubating the cells for 6 h, the fluorescence localization of the cells was observed under an IX73P1F fluorescence microscope (Olympus, Japan).
[0092] like Figure 8As shown, compared with the free Dz4 group, the cells in the APFP / Dz4 or PFP / Dz4 complex-treated group showed obvious green fluorescence, among which the fluorescence intensity of the APFP / Dz4 complex-treated group was significantly higher than that of the PFP / Dz4 complex-treated group, indicating that the APFP vector has a higher targeting ability to B16F10 cells. Compared with the non-targeted vector PFP, the APFP vector can more efficiently achieve the intracellular delivery of Dz4 in tumor cells. It is worth noting that when the nucleolin on the surface of B16F10 cells was shielded by the free nucleic acid aptamer AS1411, the fluorescence intensity of the cells in the APFP / Dz4 complex-treated group was significantly reduced, while the fluorescence intensity of the PFP / Dz4 complex-treated group did not change significantly, proving that the enhanced tumor targeting of the APFP vector should be attributed to the successful modification of the aptamer AS1411. At the same time, the same experimental operation was performed on NIH-3T3 cells, and the fluorescence intensity of the cells in the APFP / Dz4 complex and PFP / Dz4 complex treatment groups was similar, both weaker than the B16F10 cells after APFP / Dz4 complex treatment, indicating that both APFP and PFP vectors have certain transfection ability in NIH-3T3 cells, but due to the low expression of nucleolin on the surface of NIH-3T3 cells, the APFP vector did not show its targeting advantage. In addition, the shielding of free AS1411 did not affect the fluorescence intensity of the cells in the APFP / Dz4 complex and PFP / Dz4 complex treatment groups, further confirming that the APFP vector does not have specific targeting ability for normal cells. In summary, the APFP vector prepared by the present invention has a high targeting to B16F10 cells, and can deliver Dz4 into tumor cells more efficiently than the PFP vector.
[0093] Example 9
[0094] 2×10 5 Mouse melanoma B16F10 cells were seeded into 6-well plates at a density of 10 cells / well. 2 mL of complete medium was added to each well and 5% (v / v) CO 2 Cultured overnight in an incubator. After the cell confluence reached 70%, a fluorescently labeled PFP / Dz4 or APFP / Dz4 nanocomplex (N / P ratio of 20.0) was prepared as described in Example 6, added to serum-free DMEM medium and replaced with the original cell culture medium, so that the concentration of DNAzyme in the medium after addition was 3 µg / mL. After incubating the cells for 6 h, the complete medium was replaced and cultured for 48 h. Cell RNA was extracted as in Example 2, and the expression level of cell PD-L1 mRNA was detected by qRT-PCR.
[0095] The results are as follows Fig. 9As shown in the figure, compared with the control group, free Dz4 group and nonsense DNA enzyme iDz4 treatment group, the PFP / Dz4 and APFP / Dz4 nanocomplex treatment groups significantly reduced the PD-L1 mRNA expression of mouse melanoma cells B16F10, and the APFP / Dz4 nanocomplex treatment group was slightly better than the PFP / Dz4 nanocomplex treatment group, thanks to the tumor targeting brought by the aptamer AS1411. In addition, the total cell protein was extracted as in Example 3, and the cell PD-L1 protein expression level was detected by Western blotting. The results are shown in Figure 3. Fig.10 As shown, similar to the mRNA expression level, the PD-L1 protein expression levels of cells in the PFP / Dz4 and APFP / Dz4 nanocomplex treatment groups were lower than those in other groups. It can be seen that the APFP / Dz4 nanocomplex prepared by the present invention can target and degrade PD-L1 mRNA in tumor cells and effectively inhibit the expression of PD-L1 in tumor cells.
[0096] Example 10
[0097] CD8 + T cells were co-cultured with mouse melanoma cells B16F10 to detect the effect of Dz4 delivery on the expression of PD-L1 in B16F10 cells and the function of immune-related cells. + The methods for obtaining, culturing and activating T cells are as follows:
[0098] A 6-month-old female C57BL / 6 mouse (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) was killed by cervical dislocation and immediately immersed in 75% (v / v) ethanol solution for 5 min. The mouse spleen was removed with sterile tweezers and placed in a culture dish containing pre-cooled Hanks balanced salt solution (HBSS) containing 2% (v / v) fetal bovine serum. Excess connective tissue and fat were cut off and the mouse spleen was gently ground into a chylomicron-like liquid with the end of a sterile syringe. After filtering through a 70 µm cell filter, a mouse spleen single cell suspension was obtained. g The cells were centrifuged for 10 min, the supernatant was discarded, and the cells were resuspended in HBSS solution containing 2% (v / v) fetal bovine serum and 1 mM ethylenediaminetetraacetic acid (EDTA) to a final density of 1 × 10 8 cells / mL. + The cells were sorted according to the instructions of the T cell isolation kit (Stemcell, Canada). The separated cells were CD8 +T cells. Sterile PBS solution containing 1 μg / mL CD3 antibody and 3 μg / mL CD28 antibody (Thermo Fisher Scientific, USA) was added to the 6-well plate at 2 mL / well. After incubation at 37°C for 2 h, the PBS solution in the well was removed to obtain a 6-well plate coated with CD3 antibody and CD28 antibody. CD8 + T cells were expressed at 3×10 6 The cells were resuspended at a density of 10 cells / mL and added to a 6-well plate coated with an antibody. 100 ng / mL of recombinant mouse interleukin-2 (PeproTech, USA) was added to the culture medium and incubated for 1-3 days to obtain activated CD8 + T cells.
[0099] 2×10 5 Mouse melanoma B16F10 cells were seeded into 6-well plates at a density of 10 cells / well. 2 mL of complete medium was added to each well and the plates were incubated at 37 °C and 5% (v / v) CO 2 Cultured overnight in an incubator. When the cell confluence reached 70%, PFP / Dz4 or APFP / Dz4 nanocomplexes (N / P ratio of 20.0) were prepared as described in Example 6, added to serum-free DMEM medium and replaced the original cell culture medium so that the concentration of DNAzyme in the medium after addition was 3 µg / mL. After incubating the cells for 6 h, the complete medium was replaced and cultured for another 48 h. T cell proliferation was determined by CFSE dilution assay using Cell Trace Carboxyfluorescein diacetate succinimidyl ester (CFSE) cell proliferation kit (Thermo Fisher Scientific, USA): activated CD8 + T cells were incubated with CFSE dye (resuspended in DMSO at a concentration of 5 mM) in serum-free RPMI-1640 medium at 37°C for 20 min (to a final concentration of 5 μM), and then an equal volume of fresh serum-free RPMI-1640 medium was added. The cells were resuspended in RPMI-1640 medium containing 10% (v / v) serum and co-cultured with treated B16F10 cells at a ratio of 10:1 for 48 h, and the fluorescence expression of CFSE-labeled cells was analyzed by flow cytometry.
[0100] The results are as follows Fig.11 As shown, compared with the other groups, CD8 +T cell proliferation was significantly increased in the APFP / Dz4 nanocomplex-treated group. + T cell proliferation is the most obvious. PD-L1 and CD8 + Binding of PD-1 on the surface of T cells can trigger a variety of immunosuppressive mechanisms, inhibiting CD8 + T cell proliferation and activation, and the reduction of PD-L1 expression can relieve this inhibition to a certain extent. Therefore, the APFP / Dz4 nanocomplex prepared by the present invention can reduce the expression of PD-L1 in tumor cells by achieving tumor cell targeted delivery of Dz4, thereby restoring CD8 + The proliferation capacity of T cells.
[0101] Embodiment 11
[0102] 6×10 3 Mouse melanoma B16F10 cells were seeded into 96-well plates at a density of 10 cells / well, and 200 μL of complete medium was added to each well. The plates were incubated at 37°C with 5% (v / v) CO 2 The cells were cultured overnight in an incubator. When the cell confluence reached 70%, PFP / Dz4 or APFP / Dz4 nanocomplexes (N / P ratio of 20.0) were prepared as described in Example 6, added to serum-free DMEM medium and replaced with the original cell culture medium, so that the concentration of DNAzyme in the medium after addition was 3 µg / mL. After incubating the cells for 6 h, the complete medium was replaced and cultured for 48 h. Activated CD8 + T cells, CD8 + T cells were resuspended in RPMI-1640 medium containing 10% (v / v) serum and co-cultured with treated tumor cells at a ratio of 10:1. + T cell tumor cell culture group, each group has 6 replicates, and the culture is continued for 48 hours. Gently remove the supernatant and suspended CD8 + T cells, replace with serum-free DMEM medium, add 20 μL MTT solution (5 mg / mL) to each well, incubate at 37°C for 4 h, and discard the medium. Add 200 μL DMSO to each well and shake for 3 min to fully dissolve the formazan crystals, and record the OD value of each well at 490 nm. The cell viability calculation formula is as follows:
[0103] Cell viability (%) = (A 共培养孔 -A 空白孔 ) / (A 单独培养孔 -A 空白孔 )×100%
[0104] Among them, A 共培养孔Tumor cells treated with different nanocomplexes and CD8 + T cells co-cultured and CD8 + The OD value of T cells was measured after A 单独培养孔 is the OD value measured after tumor cells treated with different nanocomplexes were cultured separately, A 空白孔 The OD value is measured after adding only DMEM cell culture medium without cells.
[0105] like Fig.12 As shown in the figure, compared with other groups, the cell viability of the PFP / Dz4 and APFP / Dz4 nanocomplex-treated groups was significantly reduced, indicating that tumor-targeted delivery of Dz4 can effectively increase the number of CD8 + T cells kill tumor cells.
[0106] Example 12
[0107] Tumor cells and CD8 + T cells were co-cultured and the culture supernatant was collected. According to the instructions of the enzyme linked immunosorbent assay (ELISA) kit (Shanghai, China), the contents of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and interleukin-2 (IL-2) in the co-culture supernatant were determined. The specific process is as follows: standard samples and culture supernatant samples were added to the enzyme-labeled wells pre-coated with the corresponding primary antibodies. After incubation, the corresponding secondary antibodies labeled with biotin were added. Then, they were combined with HRP-labeled streptavidin to form immune nanocomplexes. After incubation and washing, the unbound enzymes were removed. Then, the colorimetric substrate tetramethylbenzidine was added to produce blue, which was converted into the final yellow under the action of acid. Finally, the OD value of the reaction well sample was measured at 450 nm. The cytokine concentration in the sample was proportional to the OD value. The concentration of cytokines in the sample was calculated by drawing a standard curve.
[0108] like Fig.13 As shown, tumor cells treated with PFP / Dz4 and APFP / Dz4 nanocomplexes can stimulate CD8 + The secretion of T cell immune-related cytokines was significantly stimulated by APFP / Dz4 nanocomplexes, indicating that tumor-targeted delivery of Dz4 can achieve CD8 + Effective activation of T cells.
[0109] Example 13
[0110] The tumor targeting of APFP / Dz nanocomplex was verified by detecting the distribution of drugs in mice with melanoma lung metastasis: A number of 6-month-old female C57BL / 6 mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., with a rate of 6.0×10 per mouse. 5 The mouse melanoma lung metastasis model was constructed by injecting B16F10 cell suspension through the tail vein at a dose of 1 cell. After 21 days, 9 mice were randomly selected and divided into 3 groups: free Dz4, PFP / Dz4 and APFP / Dz4. Cy5 fluorescently labeled DNAzyme Cy5-Dz4 (synthesized by Sangon Biotech Co., Ltd.) was synthesized, and PFP / Cy5-Dz4 and APFP / Cy5-Dz4 nanocomposites (N / P ratio of 20.0) were prepared according to the method described in Example 6, and administered by tail vein injection. The dosage was calculated based on Cy5-Dz4 as 0.5 mg / kg mouse body weight. At three time points of 1 h, 4 h, and 24 h, one mouse was taken out from each group and killed, and the heart, liver, spleen, lung and kidney tissues were dissected and removed. Organ imaging was performed using the small animal in vivo imaging system IVISSpectrum (Caliper Life Sciences, USA) to observe the distribution of drugs in various organs of mice.
[0111] like Fig.14 As shown in the figure, 1 hour after injection, the drug was distributed to various organs through blood circulation, and strong Cy5-Dz4 fluorescence signals were observed in the lungs of mice in the PFP / Cy5-Dz4 and APFP / Cy5-Dz4 groups, indicating that PFP / Cy5-Dz4 and APFP / Cy5-Dz4 can be rapidly enriched in the tumor site at 1 hour after systemic administration. Thanks to the tumor targeting effect provided by the aptamer AS1411, the enrichment of APFP / Cy5-Dz4 in the lungs of mice was more obvious, and the lungs of mice still maintained strong fluorescence signals at 4 hours and 24 hours after injection, indicating that the APFP / Dz4 nanocomplex can be accurately and efficiently enriched in the tumor site, providing a good foundation for the subsequent effects.
[0112] Embodiment 14
[0113] A number of 6-month-old female C57BL / 6 mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) were purchased to construct a melanoma lung metastasis mouse model. The construction process and drug administration process are as follows: Fig.15 As shown, 6.0×10 5The mouse melanoma lung metastasis model was constructed by injecting B16F10 cell suspension through the tail vein at a dose of 10 cells. The mice after tumor inoculation were randomly divided into 5 groups: Control group (only injected with normal saline), APFP / siRNA group, PFP / Dz4 group, APFP / Dz4 group and APFP / iDz4 group. At the same time, a normal control group consisting of healthy mice (referred to as Normal group) was set up, with 6 mice in each group. Starting from the 6th day after the injection of tumor cells, the drug was injected once every three days through the tail vein (the dosage was calculated based on Dz4 as 0.5 mg / kg mouse body weight), for a total of five times. On the third day after the last administration, all mice were killed, the main organs of the mice were dissected and removed, and the distribution of lung tumors in the mice was observed.
[0114] The results are as follows Fig.16 As shown in the figure, compared with the Control group and APFP / iDz4 group, the number of lung tumor nodules in the APFP / siRNA group, PFP / Dz4 group, and APFP / Dz4 group mice was significantly reduced. Compared with the PFP / Dz4 group, the APFP / Dz4 group mice had a more obvious inhibition of lung tumor growth, achieving a therapeutic effect similar to that of the APFP / siRNA group, which also shows that the APFP vector can deliver the DNAzyme Dz4 to the lung tumor site of mice in a targeted manner, and the specific cleavage of the target gene PD-L1 by Dz4 achieves the effect of inhibiting tumor growth, and its effect is close to that of siRNA.
[0115] Embodiment 15
[0116] Analysis of tumor tissue infiltrating lymphocytes by flow cytometry: The lung tumor tissues of each group of mice in Example 14 were separated and cut into homogenate with ophthalmic scissors, and then added to HBSS solution containing 1 mg / mL collagenase IV (Beijing Jintai Hongda Biotechnology Co., Ltd., China) and 10 μL / mL DNase I (NEB, UK), and incubated at 37 ° C for 2 h to digest them. The digested cell suspension was filtered through a 70 μm cell strainer to remove cell clumps, carefully superimposed on the surface of lymphocyte separation solution (Solebo, China) (ratio 1:1), and heated at room temperature for 500-900 g Centrifuge for 20 minutes. Pipette the milky white lymphocyte layer into a test tube containing 4-5 mL of cell washing solution, mix thoroughly, and g The cells were centrifuged for 20 min. The precipitate was washed twice to obtain tumor tissue infiltrating lymphocytes. The obtained cells were resuspended in PBS solution containing 2% (v / v) fetal bovine serum to a cell density of 1×10 5 -10 8The obtained cells were stained with APC-CD3, FITC-CD4 and PE-CD8 fluorescent labeled antibodies (eBioscience, USA), and the staining was analyzed by flow cytometry.
[0117] The results are as follows Fig.17 and Figure 3 As shown in .19A, CD3+ cells represent the total amount of T cells in the tumor site. Compared with the control group and APFP / iDz4 group, the total amount of T cells in the tumor tissues of mice in the APFP / siRNA, PFP / Dz4 and APFP / Dz4 complex treatment groups increased slightly. + Further analysis of CD4 + T cells and CD8 + T cell numbers, such as Fig.18 As shown, CD8 T cells, which represent cytotoxic T cells, were expressed in APFP / siRNA, PFP / Dz4, and APFP / Dz4 complex treatment groups. + The degree of T cell infiltration was significantly increased. The quantitative results of the ratio of the two cells ( Fig.19 B) shows that CD8 + T cells / CD4 + The T cell values increased significantly in the APFP / siRNA, PFP / Dz4 and APFP / Dz4 complex treatment groups, indicating that the treatment of these three complexes prompted T cells in the tumor site to differentiate into cytotoxic T cells, and this tendency often represents the activation of the local immune system and the enhancement of the ability to kill tumor cells. Among them, the APFP / Dz4 treatment group showed more CD8 + T cell infiltration was similar to that of the APFP / siRNA group, and this result was consistent with the previous degree of tumor growth inhibition, indicating that APFP / Dz4 treatment can achieve tumor-targeted delivery of Dz4, thereby increasing the recruitment and infiltration of cytotoxic T cells in the tumor site to achieve anti-tumor efficacy.
[0118] Example 16
[0119] Immunohistochemical staining to detect the expression of immune-related indicators in mouse lung tumor tissue: Take the mouse lung tumor tissue in Example 14, fix it in 4% (m / m) paraformaldehyde solution, and embed it in paraffin. The paraffin-embedded tissue was cut into 4 μm thick slices with a slicer, flattened in water and attached to a glass slide, and then dried in a 60 ° C constant temperature box for immunohistochemical staining. The slices were dewaxed with xylene solution, 100%, 95% and 85% (v / v) ethanol solution and distilled water in turn. The dewaxed tumor tissue slices were heat-antigen repaired with EDTA antigen repair solution, and then 3% (m / m) hydrogen peroxide solution was dripped on the tissue surface and incubated at room temperature for 15 min. The slices were placed in a wet box, and blocking goat serum (Solebo, Beijing, China) was added, and blocked at 37 ° C for 30 min. Primary antibody solution (anti-PD-L1, anti-CD8 and anti-granzyme-B, purchased from Abcam, USA) diluted at a ratio of 1:500 was added to the tissue and incubated overnight in a humidified box at 4°C. The tissue was washed three times with PBS buffer, and HRP-labeled secondary antibody was added and incubated at room temperature for 50 min. Finally, the sections were stained with the ready-to-use color developer diaminobenzidine (DAB) for 10 min and counterstained with hematoxylin stain. The sections were observed and photographed under a microscope.
[0120] The results are as follows Fig. 20 As shown in the figure, the number of PD-L1 positive cells in the APFP / Dz4 group was significantly reduced compared with other groups, reaching a level comparable to that in the APFP / siRNA group, indicating that the APFP / Dz4 nanocomplex effectively reduced the expression of PD-L1 in the tumor site. In addition, the detection of CD8 expression also showed that CD8 in the tumor tissue of the APFP / Dz4 group + Increased T cell infiltration, led by CD8 + Granzyme-B released by T cells also showed a corresponding increase in expression level in the APFP / Dz4 group. This shows that the treatment of APFP / Dz4 nanocomplex can achieve tumor-targeted delivery of Dz4, thereby activating the immune response at the tumor site and using the body's own immune ability to kill tumor cells.
[0121] Embodiment 17
[0122] Take the mouse lung tumor tissue in Example 14, homogenize it with a tissue homogenizer, and determine the content of immune-related cytokines TNF-α, IFN-γ and IL-2 in the tumor tissue homogenate according to the instructions of the ELISA kit. The specific process is as follows: add the standard and tumor tissue homogenate sample to the enzyme-labeled well pre-coated with the corresponding primary antibody, and after incubation, add the corresponding secondary antibody labeled with biotin. Then combine with HRP-labeled streptavidin to form an immune nanocomplex, and then incubate and wash to remove the unbound enzyme, and then add the color-developing substrate TMB to produce blue, which is converted into the final yellow under the action of acid. Finally, the OD value of the reaction well sample is measured at 450 nm. The cytokine concentration in the sample is proportional to the OD value, and the concentration of the cytokine in the sample is calculated by drawing a standard curve.
[0123] The results are as follows Fig.18 As shown in the figure, compared with the other groups, the level of immune-related cytokines in tumor tissues of the APFP / Dz4 group was significantly increased, which was comparable to the level of the APFP / siRNA group, indicating that the treatment of APFP / Dz4 nanocomplex can achieve tumor-targeted delivery of Dz4, promote the secretion of immune-related cytokines, and thus increase CD8 + The proliferation and killing ability of T cells. Sequence Listing <110> Jilin University <120> A deoxyribozyme targeting PD-L1 gene, a targeted delivery vector, a tumor-targeted nanocomplex, and applications of the enzyme <160> 12 <170> SIPOSequenceListing 1.0 <210> 1 <211> 33 <212> DNA <213> Artificial Sequence() <400> 1 gtgcaagtgg gctagctaca acgaagcctg gca 33 <210> 2 <211> 33 <212> DNA <213> Artificial Sequence() <400> 2 atatcctcag gctagctaca acgagttttg gga 33 <210> 3 <211> 33 <212> DNA <213> Artificial Sequence() <400> 3 tgaatataag gctagctaca acgagccagc aaa 33 <210> 4 <211> 33 <212> DNA <213> Artificial Sequence() <400> 4 ctgtgaatag gctagctaca acgaaatgcc agc 33 <210> 5 <211> 33 <212> DNA <213> Artificial Sequence() <400> 5 caccacgtag gctagctaca acgaaagtcc ttt 33 <210> 6 <211> 33 <212> DNA <213> Artificial Sequence() <400> 6 agtacaccag gctagctaca acgataacgc aag 33 <210> 7 <211> 33 <212> DNA <213> Artificial Sequence() <400> 7 cctctcctgg gctagctaca acgacacaaa ctg 33 <210> 8 <211> 33 <212> DNA <213> Artificial Sequence() <400> 8 agggcagcag gctagctaca acgattccct tca 33 <210> 9 <211> 33 <212> DNA <213> Artificial Sequence() <400> 9 gaagggcagg gctagctaca acgaatttcc ctt 33 <210> 10 <211> 33 <212> DNA <213> Artificial Sequence() <400> 10 tcagcgtgag gctagctaca acgaacgctt gta 33 <210> 11 <211> 33 <212> DNA <213> Artificial Sequence() <400> 11 ctgtgaatgg ctacctacaa cgaaaatgcc agc 33 <210> 12 <211> 33 <212> DNA <213> Artificial Sequence() <400> 12 agtacaccgg ctacctacaa cgaataacgc aag 33
Claims
1. A tumor-targeting nanocomplex loaded with a DNAzyme molecule, which is prepared by the method described in the following steps: (1) Dissolve 45-55 mg PAMAM and 50-60 mg heptafluorobutyric anhydride in 6-10 mL methanol, stir at room temperature for 36-50 h, then place in a dialysis bag with a molecular weight cutoff of 3000-4000 Da, dialyze in deionized water for 48-72 h, and freeze-dry the dialyzed product in the bag overnight to obtain a fluorinated PAMAM carrier powder; (2) Take 50-60 mg of the fluorinated modified PAMAM carrier powder obtained in step (1) and dissolve it in 2-4 mL of PBS solution to obtain solution A; take another 70-80 mg of maleimide-polyethylene glycol-succinimide ester Mal-PEG 5000 -NHS was dissolved in 2-4 mL of PBS solution to obtain solution B; solution A and solution B were mixed and stirred at room temperature for 36-50 h, then placed in a dialysis bag with a molecular weight cutoff of 7000-9000 Da, dialyzed in deionized water for 48-72 h, and the dialyzed product in the bag was freeze-dried overnight to obtain Mal-PEG 5000 - FP powder; (3) OD 260 The thiol-modified aptamer AS1411 with a concentration of 15-30 was dissolved in 4-6 mL PBS solution, and tris(2-carboxyethyl)phosphine with a final concentration of 8-12 mM was added, and then stirred at room temperature for 1-2 h to obtain solution C; 40-50 mg of Mal-PEG obtained in step (2) was taken. 5000 -FP powder was dissolved in 4-6 mL PBS solution to obtain solution D; solution C and solution D were mixed, stirred at room temperature for 20-30 h, and then placed in a dialysis bag with a molecular weight cutoff of 7000-9000 Da, dialyzed in deionized water for 48-72 h, and the dialyzed product in the bag was freeze-dried overnight to obtain a dendritic polymer derivative, namely, the tumor-targeted delivery carrier AS1411-PEG-FP powder; (4) The deoxyribozyme molecule targeting the PD-L1 gene whose nucleotide sequence is shown in SEQ ID NO. 4 and the tumor-targeted delivery carrier AS1411-PEG-FP powder obtained in step (3) are dissolved in nuclease-free water at a mass ratio of 1:20-100 and mixed, and then incubated at 0-40° C. for 20-40 min to obtain a tumor-targeted nanocomplex loaded with the deoxyribozyme molecule.
2. Use of the tumor-targeted nanocomplex loaded with DNAzyme molecules as claimed in claim 1 in the preparation of drugs for treating melanoma.
